Drug Trial Radar · NCT03556202
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
Last checked: Nov 20, 2026Latest source record: Mar 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,936
Actual
Start
Sep 3, 2018
Primary completion
Feb 7, 2022
Study completion Feb 7, 2022
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jun 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
Conditions
- Psoriasis
Interventions
MirikizumabDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Static Physician's Global Assessment Among Those Who Entered the Study With a sPGA of 0,1Time frame: Week 104
- Percentage of Participants Who Maintained a ≥90% Improvements in Psoriasis Area and Severity Index (PASI) 90 Among Those Who Entered the Study With a PASI 90Time frame: Week 104
Locations
229 sites in 19 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Zenith Research, Inc.
Beverly Hills, California
California Dermatology & Clinical Research Institute
Encinitas, California
First OC Dermatology
Fountain Valley, California
Keck School of Medicine University of Southern California
Los Angeles, California
Dermatology Clinical Trials
Newport Beach, California
San Luis Dermatology & Laser Clinic
San Luis Obispo, California
Clinical Science Institute
Santa Monica, California
Univ of Connecticut
Farmington, Connecticut
Florida Academic Centers Research and Education, LLC
Coral Gables, Florida
Renstar Medical Research
Ocala, Florida
Park Avenue Dermatology
Orange Park, Florida
ForCare Clinical Research
Tampa, Florida
Dermatologic Surgery Specialists, PC
Macon, Georgia
Meridian Clinical Research
Savannah, Georgia
Advanced Clinical Research LLC
Meridian, Idaho
University Dermatology
Darien, Illinois
Arlington Dermatology
Rolling Meadows, Illinois
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
The Indiana Clinical Trials Center
Plainfield, Indiana
The South Bend Clinic Center for Research
South Bend, Indiana
Forefront Research
Louisville, Kentucky
DelRicht Research
Baton Rouge, Louisiana
Dermatology and Skin Cancer Specialists
Rockville, Maryland
Lawrence J Green, M.D, LLC
Rockville, Maryland
ORA, Inc
Andover, Massachusetts
Central Dermatology PC
St Louis, Missouri
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Mount Sinai School of Medicine Dermatology Clinical Trials
New York, New York
PMG Research of Cary, LLC
Cary, North Carolina
University of North Carolina Dermatology and Skin Cancer Cen
Chapel Hill, North Carolina
PMG Research of Wilmington
Wilmington, North Carolina
Bexley Dermatology Research
Bexley, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Wright State Univ School of Medicine
Fairborn, Ohio
Oregon Dermatology and Research Center
Portland, Oregon
Oregon Medical Research Center
Portland, Oregon
Oregon Health and Science University
Portland, Oregon
The Pennsylvania Centre for Dermatology, LLC
Exton, Pennsylvania
Clinical Partners, LLC
Johnston, Rhode Island
Showing 40 of 229 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.